These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17382154)

  • 1. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.
    Torres-Roca JF; DeSilvio M; Mora LB; Khor LY; Hammond E; Ahmad N; Jove R; Forman J; Lee RJ; Sandler H; Pollack A
    Urology; 2007 Mar; 69(3):505-9. PubMed ID: 17382154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
    Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
    J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
    Li R; Heydon K; Hammond ME; Grignon DJ; Roach M; Wolkov HB; Sandler HM; Shipley WU; Pollack A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4118-24. PubMed ID: 15217948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
    Chakravarti A; Heydon K; Wu CL; Hammond E; Pollack A; Roach M; Wolkov H; Okunieff P; Cox J; Fontanesi J; Abrams R; Pilepich M; Shipley W;
    J Clin Oncol; 2003 Sep; 21(17):3328-34. PubMed ID: 12947069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome.
    Chatterjee D; Sabo E; Tavares R; Resnick MB
    Clin Cancer Res; 2008 May; 14(10):2994-3001. PubMed ID: 18483365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of phosphorylated-signal transduction and activators of transcription 3 in detecting prostate cancer from negative biopsies.
    Han G; Yu JY; Chen YD; Cao XL; Zhu J; Wang W; Wang XX; Zhang X; Yan JQ; Gao JP
    Eur J Surg Oncol; 2012 Apr; 38(4):367-73. PubMed ID: 22261084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer.
    Horinaga M; Okita H; Nakashima J; Kanao K; Sakamoto M; Murai M
    Urology; 2005 Sep; 66(3):671-5. PubMed ID: 16140113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer.
    Aziz MH; Manoharan HT; Church DR; Dreckschmidt NE; Zhong W; Oberley TD; Wilding G; Verma AK
    Cancer Res; 2007 Sep; 67(18):8828-38. PubMed ID: 17875724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
    Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
    BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour.
    Chang KC; Wu MH; Jones D; Chen FF; Tseng YL
    J Pathol; 2006 Oct; 210(2):224-33. PubMed ID: 16917804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.